Literature DB >> 15705269

Gender-specific predictors of genital herpes vaccine acceptance in a college population.

B A Auslander1, S L Rosenthal, P A Succop, L M Mills, L R Stanberry, D I Bernstein.   

Abstract

Vaccines represent one promising method for reducing the sexually transmitted disease (STD) epidemic. This study evaluated whether influences on the decision to accept a genital herpes vaccine differed by gender. In all, 518 college students completed a questionnaire on sexual history, health beliefs, and acceptance of a potential genital herpes vaccine. Each predictor variable plus a gender interaction term were analysed in separate logistic regression models. Follow-up analyses were performed by gender for outcomes that displayed significant interactions. Results indicated that a prior history of an STD and increased perception of risk for acquiring genital herpes were significant predictors of vaccine acceptance for men, while younger age and concerns about vaccine safety were significant predictors for women. Endorsement of a vaccine strategy targeting sexually experienced people was an influential factor for both genders, but was a much stronger one for women. Results suggest that gender-specific strategies may be crucial to genital herpes vaccine acceptance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15705269     DOI: 10.1258/0956462052932593

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  2 in total

1.  Differences in HIV vaccine acceptability between genders.

Authors:  Lisa Kakinami; Peter A Newman; Sung-Jae Lee; Naihua Duan
Journal:  AIDS Care       Date:  2008-05

2.  Factors associated with interest in bacterial sexually transmitted infection vaccines at two large sexually transmitted infection clinics in British Columbia, Canada.

Authors:  Kara M Plotnikoff; Gina Suzanne Ogilvie; Laurie Smith; Robine Donken; Heather Nicole Pedersen; Hasina Samji; Troy Grennan
Journal:  Sex Transm Infect       Date:  2020-05-26       Impact factor: 3.519

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.